Segment Reporting (Tables)

9 Months Ended

Sep. 30, 2016

Segment Reporting

Schedule of financial information by reporting segment

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2016		2015		2016		2015
	(in thousands)
Net revenues:
Finished pharmaceutical products	$	59,058	$	57,902	$	181,368	$	158,849
API		5,165		5,966		10,254		15,758
Total net revenues		64,223		63,868		191,622		174,607
Gross profit:
Finished pharmaceutical products		28,621		19,302		85,042		44,789
API		(1,009)		(1,724)		(814)		(613)
Total gross profit		27,612		17,578		84,228		44,176
Operating expenses		21,815		21,326		64,026		65,445
Income (loss) from operations		5,797		(3,748)		20,202		(21,269)
Non-operating income (expenses)		204		(528)		(633)		567
Income (loss) before income taxes	$	6,001	$	(4,276)	$	19,569	$	(20,702)

Schedule of net revenues in the finished pharmaceutical products segment

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2016		2015		2016		2015
	(in thousands)
Finished pharmaceutical products net revenues:
Enoxaparin	$	15,363	$	21,264	$	51,049	$	64,647
Naloxone		12,407		10,519		38,222		27,944
Lidocaine		8,279		6,176		26,378		20,662
Phytonadione		8,667		5,935		23,555		10,301
Epinephrine		5,303		5,032		14,921		9,958
Other finished pharmaceutical products		9,039		8,976		27,243		25,337
Total finished pharmaceutical products net revenues	$	59,058	$	57,902	$	181,368	$	158,849

Schedule of net revenues and long-lived assets by geographic region

	Net Revenue								Long-Lived Assets
	Three Months Ended				Nine Months Ended
	September 30,				September 30,				September 30,		December 31,
	2016		2015		2016		2015		2016		2015
	(in thousands)
United States	$	62,691	$	62,955	$	188,865	$	168,705	$	103,179	$	100,404
China		—		—		—		—		34,541		28,547
France		1,532		913		2,757		5,902		14,135		13,210
United Kingdom		—		—		—		—		97		—
Total	$	64,223	$	63,868	$	191,622	$	174,607	$	151,952	$	142,161